ALK-Positive NSCLC: Alectinib Real-World First-Line Outcomes

Real-World Evidence Analysis

• October 22, 2019

Data presented at the 2019 European Society for Medical Oncology Congress demonstrated real-world outcomes of alectinib versus crizotinib and ceritinib in untreated ALK-positive NSCLC patients (n=420).

Study Design

Patient Population: Untreated ALK-positive NSCLC (n=420)

Treatment Cohorts:

• Alectinib (n=98)
• Crizotinib (n=4)
• Ceritinib (n=318)

Endpoints: Progression-free survival, overall survival, treatment continuation

Key Results

Median Progression-Free Survival:

• Alectinib: Not reached
• Crizotinib: 5.06 months
• Ceritinib: 6.41 months

6-Month PFS Rates:

• Alectinib: 83%
• Crizotinib: 50%
• Ceritinib: 55%

12-Month PFS Rates:

• Alectinib: 68%
• Crizotinib: 25%
• Ceritinib: 36%

Overall Survival:

• Alectinib median OS: Not reached
• Superior outcomes across survival metrics

Clinical Conclusions

Real-world analysis confirms alectinib efficacy in first-line ALK-positive NSCLC, with sustained progression-free and overall survival superior to earlier-generation ALK inhibitors.

Data Source

Roche ESMO 2019 presentation: Alecensa in first-line ALK-positive NSCLC

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4